JP2007527904A - グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 - Google Patents

グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 Download PDF

Info

Publication number
JP2007527904A
JP2007527904A JP2007502390A JP2007502390A JP2007527904A JP 2007527904 A JP2007527904 A JP 2007527904A JP 2007502390 A JP2007502390 A JP 2007502390A JP 2007502390 A JP2007502390 A JP 2007502390A JP 2007527904 A JP2007527904 A JP 2007527904A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
alkoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007502390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527904A5 (enExample
Inventor
スチュアート・エドワード・ブラッドリー
レバティ・ペルペチュア・ジーヴァラトナム
トーマス・マルティン・クルレ
マーティン・ジェイムズ・プロクター
ロバート・ジョン・ローリー
ジェラード・ヒュー・トーマス
アナ・バルデス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2007527904A publication Critical patent/JP2007527904A/ja
Publication of JP2007527904A5 publication Critical patent/JP2007527904A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007502390A 2004-03-08 2005-03-08 グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 Withdrawn JP2007527904A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55125404P 2004-03-08 2004-03-08
PCT/GB2005/000885 WO2005085245A1 (en) 2004-03-08 2005-03-08 Pyrrolopyridine-2-carboxylic acid hydrazides

Publications (2)

Publication Number Publication Date
JP2007527904A true JP2007527904A (ja) 2007-10-04
JP2007527904A5 JP2007527904A5 (enExample) 2008-02-07

Family

ID=34919586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007502390A Withdrawn JP2007527904A (ja) 2004-03-08 2005-03-08 グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物

Country Status (7)

Country Link
US (1) US7884112B2 (enExample)
EP (1) EP1725555B1 (enExample)
JP (1) JP2007527904A (enExample)
AT (1) ATE483708T1 (enExample)
DE (1) DE602005023965D1 (enExample)
ES (1) ES2353309T3 (enExample)
WO (1) WO2005085245A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009144056A (ja) * 2007-12-14 2009-07-02 Nagoya City ポリ乳酸用造核剤及びポリ乳酸樹脂組成物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
US8946426B2 (en) 2009-02-06 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
ES2431619T3 (es) 2009-05-07 2013-11-27 Janssen Pharmaceuticals, Inc. Derivados de indazol y aza-indazol sustituidos como moduladores de gamma-secretasa
NZ597505A (en) 2009-07-15 2013-05-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
JP6068464B2 (ja) 2011-07-15 2017-01-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド γ−セクレターゼ調節剤としての新規な置換インドール誘導体
ES2585009T3 (es) 2012-05-16 2016-10-03 Janssen Pharmaceuticals, Inc. Derivados de 3,4-dihidro-2H-pirido[1,2-a]pirazina-1,6-diona sustituidos útiles para el tratamiento de (inter alia) enfermedad de Alzheimer
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618188D0 (en) 1986-07-25 1986-09-03 Ici Plc Diamine compounds
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8813356D0 (en) 1988-06-06 1988-07-13 Ici Plc Polypeptide compounds
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
US5821241A (en) 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
DE69530683T2 (de) 1994-03-11 2004-03-25 Pharmacopeia, Inc. Sulfonamid derivate und deren verwendung
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US6001811A (en) 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors--N-substituted derivatives
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
AU5772296A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
JP3314938B2 (ja) 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
US6297269B1 (en) 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2502764A1 (en) 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
US6107309A (en) 1995-11-13 2000-08-22 Smithkline Beecham Corporation Hemoregulatory compounds
EP0874638A4 (en) 1995-11-13 1999-07-21 Smithkline Beecham Corp HEMATOREGULATORS
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
EP1007544A1 (en) 1996-02-13 2000-06-14 Akzo Nobel N.V. Serine protease inhibitors
WO1997031016A2 (en) 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US6342516B1 (en) 1998-07-31 2002-01-29 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
AU4796700A (en) 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
DE60023878T2 (de) 1999-05-18 2006-07-20 Teijin Ltd. Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
EP1201239A4 (en) 1999-08-04 2004-12-08 Teijin Ltd CCR3 CYCLIC AMINE ANTAGONISTS
EP1088824B1 (en) 1999-09-30 2004-01-07 Pfizer Products Inc. Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
AU2001227122A1 (en) 2000-01-29 2001-08-07 Lg Chem Investment Ltd. Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
JP4327398B2 (ja) 2000-02-23 2009-09-09 ジーランド・ファーマ・ア／エス 新規な抗不整脈性ペプチド
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
WO2001094310A1 (en) 2000-06-07 2001-12-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids
WO2001096346A1 (en) 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
AU2001279612A1 (en) 2000-08-18 2002-03-04 H. Lundbeck, A/S Substituted polyamine compounds
CA2321348A1 (en) 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
GB2369117A (en) 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
RU2003120070A (ru) 2000-12-06 2004-12-27 Авентис Фармаа Дойчланд Гмбх (De) Производные гуанидина и амидина в качестве ингибиторов фактора ха
JPWO2003037864A1 (ja) * 2001-10-29 2005-02-17 日本たばこ産業株式会社 インドール化合物及びその医薬用途
DE602004028122D1 (de) * 2003-05-21 2010-08-26 Prosidion Ltd Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009144056A (ja) * 2007-12-14 2009-07-02 Nagoya City ポリ乳酸用造核剤及びポリ乳酸樹脂組成物

Also Published As

Publication number Publication date
WO2005085245A8 (en) 2005-11-10
DE602005023965D1 (de) 2010-11-18
EP1725555A1 (en) 2006-11-29
ES2353309T3 (es) 2011-03-01
US7884112B2 (en) 2011-02-08
WO2005085245A1 (en) 2005-09-15
US20080269277A1 (en) 2008-10-30
ATE483708T1 (de) 2010-10-15
EP1725555B1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
RU2059637C1 (ru) Гетероциклические производные замещенных 2-ациламино-5-тиазолов, способы их получения, производное замещенного 2-аминотиазола, производные 2-амино-4-фенилтиазола
JP5669691B2 (ja) グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター
JP3035253B2 (ja) 異項環置換アシルアミノチアゾールを含む医薬組成物
JP2001518895A (ja) ソマトスタチン作働薬
JPH08176145A (ja) アロイル−ピペリジン誘導体
JP2001519812A (ja) ソマトスタチン作動薬
JP2001514227A (ja) ピラジノン系トロンビン阻害薬
JP4643989B2 (ja) アンドロゲン受容体関連障害の治療に有用なインドール
JP2007527904A (ja) グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
US8158622B2 (en) Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2021233427A1 (zh) 并环化合物及其制备方法、药物组合物和应用
JP2016510784A (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
WO2005085245A9 (en) Pyrrolopyridine-2-carboxylic acid hydrazides
ES2324173T3 (es) Amidas del acido pirrolopiridin-2-carboxilico.
WO2006071775A2 (en) Novel compounds useful for bradykinin b1 receptor antagonism
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
JP2007527903A (ja) インドール−２−カルボン酸ヒドラジド化合物
WO2006059163A1 (en) Treatment of diabetes with glycogen phosphorylase inhibitors
SG181594A1 (en) [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
US8664397B2 (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
JP4824092B2 (ja) 新規なビニル様酸誘導体
CA2889538A1 (en) 1h-indole-3-carboxamide derivatives, and use thereof as p2y12 antagonists
JP2008521787A (ja) インドール−２−カルボン酸アミド
JPH05271187A (ja) ピロリジン誘導体又はその薬学的に許容される塩
HK1107984B (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071212

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110126